Nitroglycerin

Introduction Overview

Generic Name

Nitroglycerin

Brand Name

Nitro-Bid
Nitro-Dur
NitroMist
Nitrostat

Dosage Form

Sublingual tablets, lingual aerosol/spray, topical ointment, transdermal system, intravenous injection

Drug Class

Nitrates and Nitrites

Pharmacokinetics

Absorption:
Nitroglycerin is well absorbed through multiple routes including percutaneous absorption from the skin and transmucosal absorption from the oral cavity. Sublingual and lingual formulations allow rapid absorption through oral mucosa bypassing first-pass hepatic metabolism, resulting in quick onset of action within 1-2 minutes, making them ideal for acute anginal attacks. Transdermal delivery provides controlled, continuous absorption through the skin, with plasma steady-state concentrations typically reached around 2 hours after application; however, absorption rates vary considerably depending on the specific transdermal system. Oral extended-release forms have delayed onset due to first-pass metabolism but maintain prolonged plasma levels for up to 12 hours. Factors such as dry oral mucosa (xerostomia) can impair sublingual absorption, reducing efficacy. The bioavailability is significantly affected by the dosage form and route, with rapid onset forms used for acute attacks and topical/transdermal forms for prophylaxis.

Distribution:
Nitroglycerin displays approximately 60% plasma protein binding. Distribution details into specific tissues, including breast milk, remain uncertain, though small molecule size predicts potential minimal transfer. Its rapid onset and short half-life necessitate prompt delivery to target vascular tissues. It diffuses rapidly through biological membranes, targeting vascular smooth muscle primarily. Distribution to extravascular smooth muscles also occurs, contributing to effects on bronchial, biliary, gastrointestinal, ureteral, and uterine smooth muscles. Distribution volume specifics are limited, but clinical actions indicate effective delivery to coronary and systemic vessels.

Metabolism:
Nitroglycerin undergoes extensive metabolism primarily via hepatic mechanisms but with significant extrahepatic metabolism occurring in red blood cells and vascular walls. It is enzymatically converted initially to 1,3-glyceryl dinitrate and 1,2-glyceryl dinitrate and subsequently to glyceryl mononitrate, an inactive metabolite. Further metabolism yields mononitrate derivatives and then glycerol and carbon dioxide. The metabolic pathway is rapid, contributing to the drug's very short plasma half-life of 1-4 minutes. This rapid metabolism leads to a quick offset requiring appropriate dosing strategies, especially for intravenous use and continuous transdermal application. Intravenous infusion rates must consider administration set materials due to nitroglycerin’s adherence to plastics.

Elimination:
Nitroglycerin and its metabolites are eliminated predominantly via renal excretion after biotransformation to inactive metabolites. The elimination half-life for parent compound is brief, ranging between 1 to 4 minutes, necessitating continuous administration for sustained therapeutic effects. Clearance is efficient and rapid, reflecting the need for repeated or continuous dosing forms for long-term antianginal therapy. No significant accumulation typically occurs due to fast metabolism and elimination kinetics. Renal impairment does not markedly alter dosing requirements, reflecting predominant metabolic clearance rather than direct renal elimination.

Dosage Forms

Available Dosage Forms:
- Sublingual tablets: 0.3 mg, 0.4 mg, and 0.6 mg strengths (Brand: Nitrostat)
- Lingual aerosol (spray): 0.4 mg/spray (Brand: NitroMist)
- Lingual solution (spray pump): 0.4 mg/spray (Brand: Nitrolingual Pumpspray)
- Topical ointment: 2% concentration (Brand: Nitro-Bid)
- Transdermal systems: various delivery rates including 0.1 mg/hour, 0.2 mg/hour, 0.3 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 0.8 mg/hour (Brands: Nitro-Dur and Nitroglycerin Transdermal System)
- Parenteral injection concentrates for IV infusion: 5 mg/mL (50 mg), available in dilutions of 100 mcg/mL, 200 mcg/mL, and 400 mcg/mL in 5% dextrose infusion solutions

Dosages for Adults and Adolescents:
- Acute angina relief (sublingual): 0.3–0.6 mg every 5 minutes as needed, not exceeding 3 doses in 15 minutes; immediate medical attention if pain persists
- Acute angina relief (lingual aerosol): 1–2 sprays (0.4 or 0.8 mg) at onset of attack; may repeat every 5 minutes up to 3 doses
- Prophylactic use (ointment): initial dose 0.5 inch (~7.5 mg) twice daily, titrated up to 2 inches (~30 mg) as tolerated, separated by nitrate-free interval to prevent tolerance
- Prophylactic use (transdermal patch): one system applied every 24 hours; doses titrated based on clinical response with a nitrate-free interval of 10–14 hours
- IV infusion (varies depending on administration set): typically start 5 mcg/min in non-PVC set, titrate upwards by 5 mcg/min every 3-5 minutes; doses up to 200 mcg/min may be required; careful monitoring essential
- For non-ST-elevation acute coronary syndrome (NSTE ACS): 0.3–0.4 mg sublingual every 5 minutes up to 3 doses; IV use if required
- For ST-elevation myocardial infarction (STEMI): IV infusion starting at 5–10 mcg/min titrated per response
- For perioperative hypertension and induction of controlled hypotension: IV infusion starting at 5 mcg/min, titrated per blood pressure response

Specific Patient Populations:
- Hepatic impairment: no specific dosage adjustments indicated; monitor clinical response
- Renal impairment: dosage adjustment generally not required due to primary hepatic metabolism
- Geriatric patients: commence at low end of dosing range due to possible altered pharmacokinetics and sensitivity; frequent monitoring required
- Pediatric use: safety and efficacy not established; no standard dosing

Clinical guidelines emphasize careful dose titration to the minimum effective dose to achieve therapeutic goals while minimizing adverse effects such as hypotension and headache. Use of nitrate-free intervals is recommended during chronic therapy with topical/transdermal forms to prevent tolerance development.

Mechanism Of Action

Nitroglycerin is an organic nitrate that exerts its pharmacological effects primarily through the release of nitric oxide (NO) within vascular smooth muscle cells. Upon entering smooth muscle cells, nitroglycerin undergoes enzymatic bioactivation, resulting in the liberation of NO which activates the soluble guanylate cyclase enzyme. This activation increases intracellular cyclic guanosine monophosphate (cGMP) levels, which in turn leads to dephosphorylation of myosin light chains, causing smooth muscle relaxation.

This smooth muscle relaxation predominantly affects the venous capacitance vessels more than arterioles, leading to venous pooling of blood, decreased venous return (preload), and subsequently reduced myocardial oxygen demand. Arteriolar resistance is also reduced to a lesser extent, decreasing afterload. The net hemodynamic effect is a decrease in myocardial oxygen consumption, addressing the imbalance between oxygen supply and demand responsible for angina pectoris.

In addition to systemic vascular effects, nitroglycerin also directly dilates coronary arteries, improving coronary blood flow and alleviating coronary artery spasm, which is particularly beneficial in ischemic heart disease. Furthermore, nitroglycerin's vasodilation can transiently increase cardiac output initially by reducing afterload but may decrease cardiac output at higher doses or prolonged use due to reflex mechanisms.

Celularly, nitroglycerin is a functional antagonist to vasoconstrictors such as norepinephrine, acetylcholine, and histamine, relaxing smooth muscle in multiple organ systems including bronchial, biliary, gastrointestinal, ureteral, and uterine smooth muscle. These effects highlight its non-specific smooth muscle relaxation properties. Comparative studies show that unlike calcium channel blockers or beta-blockers, which act on cell ion channels or receptor sites, nitroglycerin’s unique NO-mediated mechanism provides a rapid and potent vasodilatory response that is critical for acute anginal relief. However, tolerance development with continuous use limits duration of effectiveness, which remains an area of ongoing research and clinical management strategies.

Pharmacological Actions

Direct vasodilation of vascular smooth muscle via nitric oxide-mediated cGMP pathway activation
Reduction of myocardial oxygen demand through decreased preload via venous capacitance vessel dilation
Lowering of afterload through arteriolar dilation reducing systemic vascular resistance
Coronary artery vasodilation enhancing myocardial oxygen supply and alleviating coronary spasms
Relaxation of smooth muscle in bronchial, biliary, gastrointestinal, ureteral, and uterine systems
Opposition of vasoconstrictor effects of catecholamines and other autacoids through smooth muscle relaxation
Transient increase in cardiac output due to decreased afterload followed by potential decrease with sustained dosing
Reduction of venous filling pressures and cardiac workload beneficial in heart failure and acute coronary syndromes
Potential prevention of episodic coronary artery vasoconstriction
Functional antagonism of norepinephrine, acetylcholine, and histamine on smooth muscle sites
Dose-dependent peripheral pooling of blood leading to hypotension and reflex tachycardia
Intravenous route enabling controlled titration for management of hypertension and intraoperative hypotension
Rapid onset and short duration make it ideal for immediate anginal relief
Development of tolerance with continuous use requiring dosing strategies to mitigate

Therapeutic Or Clinical Uses

Acute relief of angina pectoris symptoms in patients with coronary artery disease
Prophylactic management of angina attacks to reduce frequency and severity
Management of angina in patients with non-ST-segment elevation myocardial infarction (NSTEMI)
Adjunctive therapy in ST-segment elevation myocardial infarction (STEMI) especially with heart failure or hypertension
Treatment of perioperative hypertension and controlled induction of intraoperative hypotension during surgery
Management of hypertensive emergencies particularly associated with coronary ischemia or acute pulmonary edema [off-label]
Adjunctive therapy for acutely decompensated congestive heart failure to relieve dyspnea and decrease cardiac workload [off-label]
Reduction in myocardial oxygen demand in conditions with left ventricular systolic dysfunction
Relief of coronary artery spasm in variant angina
Used in intravenous form for titratable hemodynamic control in acute cardiac care settings
Beneficial in reducing left ventricular filling pressures in patients with substantial mitral regurgitation
Treatment of anal fissures via topical nitroglycerin preparations [related uses]
Part of comprehensive antianginal therapy often combined with beta-blockers or calcium channel blockers
Short-acting forms used in immediate anginal pain episodes; long-acting forms for maintenance therapy
Used cautiously in elderly patients especially with hypertrophic cardiomyopathy-induced angina

Side Or Adverse Effects

Common and sometimes severe headache characterized by throbbing or pulsating sensation
Hypotension which may cause dizziness, lightheadedness, or syncope especially in upright position
Cutaneous vasodilation manifests as transient facial flushing and warmth
Paradoxical bradycardia and exacerbation of angina may occur due to reflex autonomic responses
Contact dermatitis or fixed drug eruptions associated with topical ointment or transdermal use
Potential anaphylactoid reactions possibly associated with any route of administration
Hypotensive episodes are particularly dangerous when combined with phosphodiesterase-5 inhibitors
Tolerance development diminishing therapeutic effects with prolonged or excessive dosing
Nitrate dependence with withdrawal syndrome including rebound angina and ischemia
Gastrointestinal disturbances including nausea uncommon but may be reported
Hypersensitivity reactions including skin irritation from adhesives in transdermal patches
Reflex tachycardia and palpitations may result from vasodilation-induced baroreceptor activation
Flushing with localized warmth and redness of the skin
Potential worsening of angina in patients with hypertrophic cardiomyopathy
Overdose can lead to severe hypotension, methemoglobinemia, and cardiovascular collapse

Precautions

Use cautiously in patients with volume depletion or baseline hypotension to avoid severe hypotension
Continuous monitoring of blood pressure and heart rate during IV infusion is essential
Avoid use in patients with known hypersensitivity to nitroglycerin or other nitrates/nitrites
Ensure nitrate-free intervals in chronic therapy to reduce tolerance development
Careful clinical monitoring required in patients with acute myocardial infarction and congestive heart failure
Assess for dry oral mucous membranes which may reduce sublingual absorption
Use with caution in elderly due to altered pharmacokinetics and increased sensitivity
Advise patients on proper storage to maintain potency (e.g., original glass container for sublingual tablets)
Avoid application of ointment or patches on irritated, scarred, or callused skin areas to prevent skin reactions
Patients should avoid abrupt discontinuation to prevent rebound ischemia
Monitor patients receiving concomitant anticoagulants (e.g., heparin) for potential interaction
Advise patients about risk of severe hypotension if combined with PDE-5 inhibitors or soluble guanylate cyclase stimulators
Proper dosing and site rotation required when using transdermal systems to minimize skin irritation
Nitrate dependence can lead to withdrawal symptoms including worsened angina; tapering recommended if discontinuation necessary
Use during pregnancy only if clearly needed; sublingual tablets categorized as pregnancy category B

Warnings

Concomitant use with selective phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) is contraindicated due to risk of life-threatening hypotension
Concomitant use with soluble guanylate cyclase stimulators (e.g., riociguat) is contraindicated due to additive hypotensive effects
Severe hypotension can occur even at low doses especially in the upright position
Avoid use in patients with increased intracranial pressure, severe anemia, or early myocardial infarction for certain dosage forms
Tolerance to antianginal and hemodynamic effects may develop with continuous use; use dosing strategies to minimize
Potential for paradoxical bradycardia and angina exacerbation secondary to hypotension
Care required to avoid overly aggressive blood pressure reduction in hypertensive emergencies
Risk of contact dermatitis or fixed drug eruptions with topical/nitroglycerin ointment or transdermal systems
Patients should be warned about obtaining and using PDE inhibitors illicitly while on nitrates
Hemodynamic and symptomatic monitoring necessary in heart failure and acute coronary syndrome patients receiving IV nitroglycerin
Avoid application of transdermal systems to areas likely to be used for defibrillation due to electrical conduction risks
Cautious use warranted in geriatric patients due to potential comorbidities and altered drug pharmacokinetics
Withdrawal of nitroglycerin after long-term use can trigger rebound ischemic symptoms, including myocardial infarction and death
Advise patients about immediate medical evaluation if anginal pain persists after maximum recommended doses
Potential for drug interactions necessitates careful medication history and clinical monitoring

Contraindication

Known hypersensitivity to nitroglycerin, other nitrates, nitrites, or any ingredient in formulation
Use of topical nitroglycerin in patients allergic to adhesive components of transdermal systems
Use of sublingual nitroglycerin in patients with early myocardial infarction in some cases
Severe anemia
Increased intracranial pressure or cerebral hemorrhage
Concomitant use with selective phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil)
Concomitant use with soluble guanylate cyclase stimulators (e.g., riociguat)

Drug Interactions

Selective phosphodiesterase type 5 (PDE-5) inhibitors profoundly potentiate vasodilatory effects leading to severe hypotension; combination contraindicated
Soluble guanylate cyclase (sGC) stimulators (e.g., riociguat) cause additive hypotensive effects; coadministration contraindicated
Alcohol may enhance hypotensive effects; use with caution to avoid excessive blood pressure decrease
High-dose aspirin (≥1 gram) may increase nitroglycerin exposure and potentiate vasodilatory and hemodynamic actions
Antihypertensive agents may have additive hypotensive effects; dose adjustments might be needed to prevent orthostatic hypotension
Ergot alkaloids (e.g., dihydroergotamine) may antagonize coronary vasodilation and precipitate angina; concomitant use not recommended
Heparin’s anticoagulant effect may be antagonized by IV nitroglycerin; close monitoring of coagulation parameters advised
Other nitrates and nitrites may cause additive hypotension; careful dosing and monitoring required
Phenothiazines may enhance hypotensive effects; caution advised with dose adjustments as necessary
Thrombolytic agents (e.g., t-PA) may have reduced plasma levels and effect when administered with IV nitroglycerin; monitoring recommended
Use with other vasodilators can potentiate hypotensive effects; monitor closely
Interactions with drugs causing vascular relaxation can increase the risk of adverse hemodynamic effects
Concurrent administration with PDE inhibitors and nitrates carries potential for fatal outcomes; thorough medication history essential
Possible interaction with various cardiovascular drugs necessitates dose titration and clinical surveillance
Drug interactions may necessitate avoidance or careful clinical monitoring during combined use

Preparations Of The Drug

Nitroglycerin Lingual Aerosol: 0.4 mg/spray (Brand: NitroMist)
Nitroglycerin Lingual Spray Solution: 0.4 mg/spray (Brand: Nitrolingual Pumpspray)
Sublingual Tablets: 0.3 mg, 0.4 mg, and 0.6 mg strengths (Brand: Nitrostat)
Topical Ointment: 2% concentration (Brand: Nitro-Bid)
Transdermal Systems: Various delivery rates including 0.1, 0.2, 0.3, 0.4, 0.6, and 0.8 mg/hour (Brand: Nitro-Dur and Nitroglycerin Transdermal System)
Parenteral Injection Concentrate: 5 mg/mL solution to be diluted for IV infusion (available in 100, 200, and 400 mcg/mL dilutions in 5% dextrose)
Nitroglycerin in 5% Dextrose Injection: 100 mcg/mL, 200 mcg/mL, 400 mcg/mL concentrations
Available from multiple manufacturers, distributors, and repackagers under generic and brand names
Formulations incorporate excipients which may have clinical significance in some individuals; consult specific product labeling
Each formulation designed for specific routes: sublingual for rapid relief, transdermal for prophylaxis, IV for acute settings
Packaging instructions emphasize storage in original tight containers, avoidance of heat and light exposure
Transdermal systems require application to hairless, non-irritated skin and rotation of application sites
Parenteral preparations should be diluted and stored according to manufacturer specifications, avoiding certain plastics and filters
Lingual aerosols and solutions contain highly flammable propellants or alcohol; handle with care to avoid ignition
Multiple-dose containers require tight closure immediately after use to maintain potency, particularly sublingual tablets and ointments